An LDL-C of 10 mg/dL on triple therapy (rosuvastatin, ezetimibe, and alirocumab) is not too low and is safe to continue.
Evidence Supporting Very Low LDL-C Levels
Current guidelines and clinical trial data demonstrate no safety concerns with LDL-C levels below 25 mg/dL or even below 15 mg/dL. The 2019 ACC/AHA guidelines establish treatment thresholds (≥70 mg/dL for very high-risk patients) but do not define a lower safety limit 1. More importantly, the 2024 International Lipid Expert Panel explicitly targets LDL-C <55 mg/dL (<1.4 mmol/L) for post-ACS patients and states that achieving these very low levels reduces cardiovascular events 2.
Safety Data from Clinical Trials
The ODYSSEY program pooled analysis specifically examined patients achieving LDL-C <25 mg/dL and <15 mg/dL on alirocumab 3:
- 839 patients (25.1%) achieved two consecutive LDL-C values <25 mg/dL
- 314 patients (9.4%) achieved <15 mg/dL
- No increase in overall adverse events compared to those with higher LDL-C levels
- No increase in neurocognitive events at these very low levels
- Follow-up extended to 104 weeks, providing reassurance about longer-term safety
The FOURIER trial demonstrated continued cardiovascular benefit down to LDL-C levels of 10 mg/dL with no safety plateau 4. Post hoc analyses from ODYSSEY OUTCOMES showed that mortality actually declines with lower achieved LDL-C levels down to 30 mg/dL (adjusted P=0.017 for linear trend) 4.
Your Current Regimen is Appropriate
Your triple combination therapy represents guideline-concordant intensive lipid-lowering for very high-risk patients 1, 2:
- Maximally tolerated statin (rosuvastatin)
- Ezetimibe added when LDL-C remained ≥70 mg/dL
- PCSK9 inhibitor (alirocumab/Repatha) added when LDL-C remained elevated on statin plus ezetimibe
This stepwise escalation follows the 2022 ACC Expert Consensus Decision Pathway precisely 5.
Important Caveats
Monitor for One Specific Issue
The only signal requiring attention is cataracts. In the pooled ODYSSEY analysis, patients achieving LDL-C <25 mg/dL had higher cataract rates (2.6%) versus those ≥25 mg/dL (0.8%; HR 3.40,95% CI 1.58-7.35) 3. However, this finding requires context:
- No difference in cataract incidence between alirocumab and control groups overall
- The clinical significance remains uncertain
- Recommendation: Ensure routine ophthalmologic screening, but this should not prompt discontinuation of therapy
What to Actually Monitor
- Adherence to all three medications - the dramatic LDL-C reduction confirms excellent adherence
- Lipid panel every 3-6 months to ensure stability
- Liver enzymes and CK if any new symptoms develop (though routine monitoring is not required)
- Ophthalmologic examination annually given the cataract signal
Do Not Reduce or Stop Therapy
There is no evidence-based reason to reduce your current regimen. The "lower is better" paradigm for LDL-C is supported by:
- Genetic studies of individuals with lifelong very low LDL-C showing no adverse effects 4
- Clinical trial data showing continued cardiovascular benefit without safety concerns 4, 3
- Post hoc analyses demonstrating mortality benefit at these levels 4
The 2024 ILEP guidelines explicitly state that patients achieving LDL-C <30 mg/dL at 1 month had the lowest rate of cardiovascular events over 6 years with similar safety profiles compared to higher LDL-C levels 6.
Clinical Context Matters
Your dramatic response (90→10 mg/dL) suggests you are likely at very high cardiovascular risk, which is precisely the population deriving maximum benefit from intensive LDL-C lowering 2, 6. The 2024 guidelines recommend this exact approach for post-ACS patients and those with established ASCVD 2.
Continue your current triple therapy without modification. Your LDL-C of 10 mg/dL represents optimal cardiovascular risk reduction based on the best available evidence.